Moving cannabis to a category of drugs that includes some common medicines will have implications for research, businesses ...
The fund returned 10.56% in 3Q 2025, outperforming its benchmark as AI and rate cuts supported growth. Review the full ...
The change would not legalize the drug on the federal level, but would ease barriers on research using cannabis.
The Goldman Sachs U.S. Equity Insights Fund returned 8.24% in Q3 2025, outperforming the S&P 500 by 12 bps. Click here to ...
During the holidays you see ribbons and bows everywhere you look. You find them on the packages under the tree and at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback